K
Power Law company profile
Kymera Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020 Unicorn
Valuation
$5.90B
Market cap · Apr/2026
Revenue
$39M
Latest reported FY
Global footprint
Where Kymera Therapeutics has talent and traffic
AI talent share
0.7%
of workforce is AI talent
(2 of 291 staff)
(2 of 291 staff)
Core AI10.34%
Other AI10.34%
Non-AI workforce28999.31%
Web traffic by country
25K
monthly visits
across markets
across markets
🇺🇸 United States63.2%
🇮🇳 India11.2%
🇪🇸 Spain7.2%
🇬🇧 United Kingdom6%
🇨🇦 Canada5.6%
Patent intelligence
$26M patent portfolio · 107 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$26M
0.44% of market cap · 2.2× the top peer Gracell Biotechnologies ($12M)
107 active patent families
Where Kymera Therapeutics innovates
BiochemistryOrganic chemistryCombinatorial chemistryPharmacologyMolecular biology
Tracks the peer median across all five Patsnap quality dimensions.
Quality vs same-sector peers
Kymera Therapeutics on the five Patsnap quality dimensions
Kymera Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Kymera Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Kymera Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Kymera Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.